Are bispecific antibody therapies being combined with other anti-myeloma therapies?

Current bispecific antibodies on the market have only been FDA approved for use by themselves, however clinical trials are actively ongoing to test them in combination with other treatments.

Watch the HealthTree University Video, led by myeloma experts, to find out more.

Bispecific Combination Clinical Trials 

Bispecific antibody therapies are currently being tested with many other anti-myeloma therapies. A combination of drugs could provide an even more effective therapy with a longer duration. There are trials for active myeloma patients and a few for those with high-risk smoldering myeloma.

These trials will test for effective combinations, best dosing amounts, side effect profiles, and more. You can look at what active clinical trials are occurring here: HealthTree Myeloma Clinical Trials

Some examples (as of July 2024) include: 

• NCT05455320: talquetamab, daratumumab and pomalidomide with or without dexamethasone 
• NCT05050097: talquetamab and other anti-cancer therapies 
• NCT05090566: elranatamab and other anti-cancer therapies 
• NCT06100237: teclistamab or talquetamab with daratumamab for high-risk smoldering